Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

AbbVie’s stock price fell over 12% after emraclidine failed to meet its primary endpoints in the company’s Phase II ...

ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of dolutegravir/lamivudine ...

Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to treat ...